ClinicalTrials.gg
Sign In
CompletedNCT00104078Updated Dec 28, 2007

Study Evaluating MYO-029 in Adult Muscular Dystrophy

A Phase 1/2 interventional study of MYO-029 in Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy and Limb-Girdle Muscular Dystrophy, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-12-28.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult patients with muscular dystrophy.

02

Conditions studied

  • Becker Muscular Dystrophy
  • Facioscapulohumeral Muscular Dystrophy
  • Limb-Girdle Muscular Dystrophy
03

In context

Muscular Dystrophy, Duchenne

480 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 109 are open to participants now.

This study's enrollment of 108 is above the median of 26 across 329 interventional studies indexed under Muscular Dystrophy, Duchenne.

Browse Muscular Dystrophy, Duchenne studies →

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Browse Wyeth studies →All Pfizer studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written informed consent.
  • Confirmed clinical and molecular diagnosis of Becker Muscular Dystrophy (BMD), Facioscapulohumeral Muscular Dystrophy (FSHD), or Limb-Girdle Muscular Dystrophy (LGMD)
  • Independently ambulatory

Exclusion criteria

Exclusion Criteria:

  • Patients with certain clinical conditions
  • Patients using steroids or other medications with the potential to affect muscle function
  • History of sensitivity to monoclonal antibodies or protein pharmaceuticals
  • Pregnant or lactating women.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
108 participants

Interventions

  • DrugMYO-029
06

What researchers measure

Primary outcomes

  1. Safety assessment

07

Study locations

9 sites
  • Washington D.C., District of Columbia 20010, United States
  • Kansas City, Kansas, United States
  • Baltimore, Maryland 21287-7519, United States
  • Boston, Massachusetts, United States
  • St Louis, Missouri, United States
  • Rochester, New York, United States
  • Columbus, Ohio, United States
  • Dallas, Texas, United States
  • Salt Lake City, Utah, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2005
First posted
Feb 23, 2005
Start
Feb 2005
CompletionActual
Jan 2007
Last update
Dec 28, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00104078
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
First posted
Feb 23, 2005
Start date
Feb 2005
Completion
Jan 2007
Last update
Dec 28, 2007

Study contacts

Medical Monitor, MD
study director · Wyeth is now a wholly owned subsidiary of Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Muscular Dystrophy, Duchenne →

Other studies from this sponsor

Wyeth is now a wholly owned subsidiary of Pfizer →

Start the discussion